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Abstract
Background The benefit of implantable defibrillators (ICDs)
for primary prevention remains debated. We analysed the
implications of prophylactic ICD implantation according to
the guidelines in 2 tertiary hospitals, and made a healthcare
utilisation inventory.
Methods Thecohortconsistedofallconsecutivepatientswith
coronary artery disease (CAD) or dilated cardiomyopathy
(DCM) receiving a primary prophylactic ICD in a contempo-
rary setting (2004–2008). Follow-up was obtained from
hospital databases, and mortality checked at the civil registry.
Additional data came from questionnaires sent to general
practitioners.
Results There were no demographic differences between the
2 centres; one had proportionally more CAD patients and
more resynchronisation therapy (CRT-D). The 587 patients
were followed over a median of 28 months, and 50 (8.5%)
patients died. Appropriate ICD intervention occurred in 123
patients (21%). There was a small difference in intervention-
free survival between the 2 centres. The questionnaires
revealed 338 hospital admissions in 52% of the responders.
Device-related admissions happened on 68 occasions, in 49/
276 responders. The most frequently reported ICD-related
admission was due to shocks (20/49 patients); for other
cardiac problems it was mainly heart failure (52/99).
Additional outpatient visits occurred in 19%.
Conclusion Over a median follow-up of 2 years, one fifth
of prophylactic ICD patients receive appropriate interven-
tions. A substantial group undergoes readmission and
additional visits. The high number of admissions points to
a very ill population. Overall mortality was 8.5%. The 2
centres employed a similar procedure with respect to patient
selection. One centre used more CRT-D, and observed more
appropriate ICD interventions.
Keywords Complications.Coronary artery disease.
Dilated cardiomyopathy.Health care resources.
Implantable cardioverter defibrillator.Primary prevention.
Mortality.Sudden cardiac death.Ventricular arrhythmias
Introduction
Implantable defibrillator (ICD) therapy is without doubt the
most effective therapy available to prevent sudden cardiac
death (SCD) in selected patient groups [1–5]. Convincing
evidence of the effectiveness of primary prophylactic ICD
therapy exists for coronary artery disease (CAD) and dilated
cardiomyopathy (DCM) [6–10]. Like most state-of-the-art
therapeutic modalities, ICD therapy is costly [11–17]. With
the current improvement in heart failure therapy, the recent
increased number of device recalls, and the trend towards
more lead failure, the debate about prophylactic ICD therapy
has shifted from ‘effectiveness’ toward ‘cost-effectiveness’
[18–22]. Nevertheless, some authors remain convinced that a
serious underutilisation continues to exist in Europe [23, 24].
Thecostsofatherapycannotbeassessedwithoutassessing
its clinical benefit. In fact, only few modern therapies—
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contrary, ICD therapy prevents SCD, an event that costs little
to nothing to treat, when an ICD is in place [25]. Cost-
effectiveness analyses showed that a large part of the lifetime
costs of a primary prophylactic ICD patient occur at the time
of ICD implantation. However, it takes years to accrue the
benefit of a primary prophylactic ICD since this effect is
time-dependent. In this perspective, the health care costs that
accumulate during these years (i.e. hospitalisation costs,
costs for unscheduled outpatient consultations) should also
be taken into account when analysing the cost-effectiveness,
especially when considering that primary prevention ICD
candidates are heart failure patients with a potential high
need for specialised care. Unfortunately, no data on the
burden of medical care are available in a real world setting
f o rt h i sk i n do fp a t i e n t si nt h eN e t h e r l a n d s .
The aim of this study was to analyse the frequency of
hospitalisation and unscheduled outpatient consultations in
primary prophylactic ICD patients, as documented in the
hospitalrecords of2 major universityhospitals,supplemented
with data obtained with a survey among general practitioners,
who could provide data on otherwise unknown admissions in
other institutions.
Methods
Study population
The study population consisted of all consecutive patients with
CAD or DCM, who received an ICD according to the ESC/
AHA/ACC 2006 guidelines for primary prophylaxis of sudden
cardiac death in the Erasmus MC between January 2004 and
July 2008, and of all similar consecutive patients in the
Amsterdam University Medical Centre (AMC) in the year
2006. The presence of CAD had to be documented clinically
by a history of a myocardial infarction according to the
definitions by ACC/AHA/ESC, if coronary artery bypass
grafting (CABG) or a percutaneous coronary intervention
(PCI) had been performed, or if significant coronary artery
stenosis was documented with coronary angiography. DCM
was defined as a primary myocardial disease with dilatation
without valvular or congenital aetiology. Patients with channe-
lopathies and specific diseases as arrythmogenic right ventric-
ular cardiomyopathy and the Brugada syndrome were
excluded.AllICDswereimplantedbyatransvenoustechnique
in the cardiac catheterisation laboratory, or if necessary by a
cardiac surgeon (e.g. for placement of epicardial leads).
Data collection
Baseline characteristics included age, gender, underlying
disease, presence of prior myocardial infarction, and left
ventricular function at the time of ICD implantation.
Follow-up started at the time of ICD implantation, with
conventional ICD control. All patients were followed at 3-
month intervals and were advised to contact the outpatient
clinic after a symptomatic event. At each follow-up visit,
arrhythmic events with stored electrograms (EGMs) were
retrieved from the device’s memory. Two independent
reviewers analysed the stored electrograms to classify the
arrhythmia and assess the appropriateness of device
classification and therapy. In case of disagreement, a third
reviewer was consulted to provide the final diagnosis.
The electronic hospital files and the electronic ICD
database were reviewed to record and understand the impact
of complications. Procedure-related complications were de-
fined as occurring within 30 days after implantation.
In order to make a better health care utilisation inventory,
we sent questionnaires to the general practitioners of 464 of
the included patients (all AMC and the first 355 Erasmus
MC patients). This questionnaire examined the frequency
and duration of hospital admissions for ICD-related prob-
lems, hospital admissions for non-ICD related cardiac
problems, and hospital admissions for other conditions.
We also asked for the number of additional outpatient visits.
Regular outpatient control visits and admissions for elective
ICD generator replacements because of battery depletion
were not taken into account. Follow-up for vital status was
obtained by consulting the civil registry. The duration of the
hospitalisation was only obtained from the AMC sample.
Follow-up was completed until 31 December 2008.
Statistical analysis
Continuous variables are expressed as the mean ± SD, or as
the median with the interquartile range (IQR) when not
normally distributed. Categorical variables are expressed as
frequency (percentage). Group differences were analysed
with Chi-square tests and independent sample T-tests where
appropriate. The assumption of normality was checked for
all variables tested. If not normally distributed, we used
non-parametric tests. Alpha was set at 0.05 for all statistical
tests. Cumulative survival and event-free rates of appropri-
ate ICD therapy were calculated according to the Kaplan-
Meier method and were compared with the log-rank test.
Patients who underwent heart transplantation were censored
alive from the moment of transplantation.
Results
Study population
The study population consisted of a total group of 587
patients: 478 patients originated from the Erasmus MC
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baseline characteristics of the study population are pre-
sented in Table 1. The median follow-up till death or the
closure date was 28 months (IQR 14–37 months). The
follow-up of the Erasmus MC patients was shorter (Table 2).
There were slightly more patients with CAD in the group
from the Erasmus MC. The mean ejection fraction was the
same. There were 5% of the patients in NYHA class I, 51%
in NYHA class II, 44% in class III, and only 1% in class IV.
Heart transplantation was performed in 17 patients of a total
of 41 patients who were on the transplantation list of the
Erasmus MC. There were significant differences in the
device type used in the two centres, with the Erasmus MC
using more cardiac resynchronisation therapy systems with
defibrillation (CRT-D).
Mortality
During the reported follow-up, 50 patients (8.5%) died
(Table 2), at a median time since implantation of 359 days
(IQR 159–759 days). The survival curves for Erasmus MC
patients and AMC patients are depicted in Fig. 1.N o
significant differences in mortality was observed between
Erasmus MC patients and AMC patients (log rank =
0.573; NS).
ICD interventions
During follow-up, 123 patients (21%) experienced at
least one episode of ventricular tachyarrhythmia trigger-
ing appropriate ICD intervention, including 16/50 of the
deceased patients (32%), and 9/41 patients (22%) who
were on the heart transplantation list. The median
interval to the first appropriate ICD intervention was
251 days (IQR 65–507 days). Differences in this
parameter between the 2 institutions were not significant.
Figure 2 shows the Kaplan-Meier curves for appropriate
ICD interventions for patients originating from both
centres. Nevertheless, the cumulative incidence of appro-
priate ICD interventions was significantly higher in
Erasmus MC patients compared with AMC Amsterdam
patients (log rank = 4.340; p-value=0.037).
Readmissions for lead and ICD problems
As obtained from the patient records, there were 54 late
complications in 47 patients (8%), similar for both
hospitals. This included 8 lead repositions, 12 lead replace-
ments of which 3 were because of a recall (Sprint Fidelis).
A total number of 27 ICD replacements occurred, including
15 replacements within 36 months and 3 pocket infections.
There were no recalls for pulse generators in this time
frame in both institutions.
Hospitalisation and unscheduled outpatient consultations
A questionnaire was sent to 464 patients. A completed
questionnaire was received from 276 patients, making the
response rate 59%. A total number of 338 hospital admissions
were reported, occurring in 144 patients (52% of the
responders, and 31% of the group to whom a questionnaire
was sent). In total, 79/144 were admitted twice; of these, 44 a
thirdtime,and27atleast4times.Themedianintervalbetween
ICD implantation and first hospitalisation was 407 days (IQR
132–800 days). The cumulative incidence of first hospital-
isation after ICD implantation is depicted in Fig. 3.N o
significant difference is observed between the centres.
Analysis of the questionnaires is presented in Table 3.
The median duration of hospitalisation was 2.5 days (IQR
1–12 days).
From the 338 reported hospital admissions, 68 (20%)
were ICD related; 180 (53%) were for other cardiac
reasons, and 90 (27%) were for non-cardiac pathology.
Figure 4 shows the distribution of the reasons per
Table 1 Baseline characteristics
Characteristic Erasmus MC n=478 AMC n=109 p value
Mean follow-up (days) 762±446 969±185 <0,0001
Age (years) 59±12 61±12 NS
Male gender 374 (78%) 84 (77%) NS
Coronary artery disease 319 (67%) 61 (56%) 0.023
Dilated cardiomyopathy 159 (33%) 45 (41%)
LVEF (%) 25±8 22±6 NS
ICD type
Single chamber 200 (42%) 65 (61%) <0.001
Dual chamber 74 (15%) 38 (35%)
CRT-D 204 (43%) 4 (4%)
CRT-D cardiac resynchronisation therapy defibrillator; LVEF left ventricular ejection fraction; NA not available
Neth Heart J (2011) 19:405–411 407admission category. Of 49 patients with an ICD-related
admission, 20 were admitted because of a shock (41%); of
99 patients with other cardiac admissions, heart failure or
associated conditions were the reason in 52 occasions
(53%). The largest non-cardiological reason for hospital
admission was related to internal medicine (25/58 patients).
Additional unscheduled cardiac outpatient consultations
were observed in 51 (19%) of the patients (Table 3).
Discussion
This study of patients in two different Dutch university
hospitals shows that in spite of an apparent different
attitude, but with formal adherence to the actual guidelines,
the outcome of the patients was completely comparable
with respect to a hard endpoint as mortality, and to a softer
endpoint as hospitalisation [26]. Nevertheless, we have
seen differences in the underlying cardiac disease of the
patients (the prevalence of coronary artery disease was
higher in Rotterdam), and in the type of implanted
defibrillation systems (higher number of CRT-D; also in
Rotterdam). The only different outcome between the 2
centers was the occurrence of appropriate ICD therapy,
which can not be explained at first glance.
Mortality The mortality is less than 10% in both centres,
even with a median follow-up of more than 2 years. These
data correspond with recent real world data [27, 28]. The
landmark trials (MADIT, MADIT II, SCDHeFT) all had a
mortality rate in the active arm of 14, 22 and 18%,
respectively, at 3 years [1–3]. This implicates that today,
the practice in the Netherlands can still be compared with
the trials as they were published. The outcome of the heart
transplantation patients, a typically censored group, was not
different in this respect from the others.
Appropriate ICD interventions (shocks/antitachycardia
pacing) In both centres, approximately one fifth of the
patients received appropriate ICD interventions, over a
median follow-up of more than 2 years. This intervention
rate is high, and supports the idea that the right patients
were selected. This patient selection was in line with the
actual guidelines and was more or less conservative,
Table 2 Follow-up data from hospital records
Characteristic Erasmus MC n=478 AMC n=109 p value
Mean follow-up (days) 762±446 969±185 <0.0001
Appropriate shocks/ATP 105 (22%) 18 (16.5%) NS
Mean time to first appropriate event (days) 313±315 414±271 NS
Late complications (patients) 38 (7.9%) 9 (8.3%) NS
Mortality 41 (8.7%) 9 (8.2%) NS
ATP anti-tachycardia pacing
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Fig. 1 Kaplan-Meier analysis, comparing mortality in both centres
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Fig. 2 Kaplan-Meier analysis, comparing the rate of first appropriate
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408 Neth Heart J (2011) 19:405–411meaning that early post infarct patients were avoided, in
line with recent studies [29, 30]. It is striking that one
centre had a higher rate of device therapy than the other,
which might be attributed to the presence of patients with
advanced heart failure (as might be suggested by the
higher proportion of CRT-D) or simply to different
programming strategies. The latter is a very likely
explanation. Although, there was no obvious difference
in the standard programming of rate cut-offs for arrhyth-
mia detection. On the other hand, differences in time to
intervention, and the use of ATP may certainly influence
t h er a t eo fi n t e r v e n t i o n s[ 31]. It is reassuring to observe
that this higher intervention rate is not associated with a
different mortality or real morbidity. Further, in both
centres, the rate of inappropriate interventions was low
as is reported elsewhere [32].
Morbidity The readmission rate was very high, and the
questionnaire did not really yield a different outcome in
respect to what was known from the hospital files e.g.
for lead reintervention. This supports the idea that the
questionnaire was reliable as well as the observation that
these patients were very ill, with a high readmission rate,
also for non-cardiac causes. This might be an indication
that more attention should be given to comorbidity in
general, before implantation [33–35]. It is known that
diabetes, renal failure and high age contribute to the
morbidity after implantation. Further, not all cardiac
admissions occurred because of device therapy. Only a
minority of admissions were reported to occur because of
shock therapy. The most important reason for admission
remains heart failure, which confirms previous findings
[38, 39].
Limitations
It might be that our method (the survey) resulted in over-
reporting, as general practitioners might have responded
more frequently if they had encountered problematic
patients. However, it was the only way to understand
what was happening with the patients at home and in the
referral centre. Further, the rate of specific complications
as reported coincided with the rate as known from the
hospital records.
Conclusions
The 2 centres behaved in a similar way with respect to
patient selection. Mortality and readmission were the
same during follow-up. However, one centre more often
used CRT, and observed a higher ICD therapy rate for
ventricular arrhythmias.
Further, the high readmission rate, mainly for heart
failure, is a reason to organise a good follow-up for these
patients. It is clear that the referring cardiologist still has a
role after implantation. This role could even increase when
it is accepted that ICD control is performed in those centres.
On the other hand, the high early complication rate
demands a tight control to improve the quality at the time
of implantation. One important measure could be to
maintain a limited number of experienced implanting
centres [36, 37]. It is clear that patient selection, according
to the actual guidelines, results in a reproducible outcome,
even in different centres.
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Table 3 Hospitalisation (≥1) and unscheduled outpatient consultations per patient as obtained from the questionnaires
Characteristic All (n=276) Rotterdam (n=224/355) Amsterdam (n=52/109) p
ICD-related hospital admission 49/276 (18%) 40/224 (18%) 9/52 (17%) NS
Cardiac hospital admission 99/276 (36%) 78/224 (35%) 21/52 (40%) NS
Other hospital admission 58/276 (21%) 48/224 (21%) 10/52 (19%) NS
Additional outpatient cardiac visit 51/276 (19%) 38/224 (17%) 13/52 (25%) NS
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